Long-term inhibition of the renin-angiotensin system in genetic hypertension: Analysis of the impact on blood pressure and cardiovascular structural changes

Journal of Hypertension

Volumn 15, Issue 4, 1997, Pages 339-348

  Lundie, Mark J ^a   Friberg, Peter ^a,b   Kline, Robert L ^c   Adams, Michael A ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Angiotensin converting enzyme inhibitors; Cardiovascular structural regression; Hypertension; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL MODEL; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG EFFICACY; HEMODYNAMICS; HEREDITARY HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0030951528     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715040-00004     Document Type: Review

References (104)

1. Freslon JL, Guidicelli JF: Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats. Br J Pharmacol 1983, 80:533-543.
2. Sano T, Tarazi RC: Differential structural responses of small resistance vessels to antihypertensive therapy. Circulation 1987, 75:618-626.
3. Gibbons GH: Angiotensin-converting enzyme inhibition and vascular structure in hypertension. J Cardiovasc Pharmacol 1991, 18 (suppl 7):S19-S24.
4. Korner PI, Jennings GL: Pathogenesis of human primary hypertension: a new approach to the identification of causal factors and to therapy. J Hypertens 1986, 4 (suppl 3):S149-S153.
5. Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients - a metaanalysis of 109 treatment studies. Am J Hypertens 1992, 5:95-110.
6. Doyle AE: Role of angiotensin-converting enzyme inhibitors in preventing or reducing end-organ damage in hypertension. J Cardiovasc Pharmacol 1992, 19 (suppl 5):S21-S27.
7. Poole-Wilson PA, Lindsay D: Advances in the treatment of chronic heart failure. BMJ 1992, 304:1069-1070.
8. Zanchetti A: Short- and long-term perspectives of antihypertensive therapy. An introduction. Am J Hypertens 1993, 6:2S-5S.
9. De Cesaris R, Ranieri G, Filitti V, Andriani A, Bonfantino VM: Forearm arterial distensibility in patients with hypertension: comparitive effects of long-term ACE inhibition and β-blocking. Clin Pharmacol Ther 1993, 53:360-367.
10. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, et al.: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilation in patients in asymptomatic systolic dysfunction. Circulation 1993, 88:2277-2283.
11. Nyborg NCB, Mulvany MJ: Lack of effect of anti-hypertensive treatment with felodopine on cardiovascular structure of young spontaneously hypertensive rats. Cardiovasc Res 1985, 19:528-536.
12. Simon AC, Levenson J, Bouthier JD, Safar ME: Effects of chronic administration of enalapril and propranolol on the large arteries in essential hypertension. J Cardiovasc Pharmacol 1985, 7: 856-861.
13. Limas C, Westrum B, Limas CJ: Comparative effects of hydralazine and captopril on the cardiovascular changes in spontaneously hypertensive rats. Am J Pathol 1984, 117:360-371.
14. Jespersen LT, Nyborg NCB, Pedersen OL, Mikkelsen EO, Mulvany MJ: Cardiac mass and peripheral vascular structure in hydralazine-treated spontaneously hypertensive rats. Hypertension 1985, 7:734-741.
15. Weiss L: Long-term treatment with antihypertensive drugs in spontaneously hypertensive rats (SHR). Effects on blood pressure, survival rate and cardiovascular design. Acta Physiol Scand 1974, 91:393-408.
16. Conn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al.: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
17. Hall JE: Intrarenal actions of converting enzyme inhibitors. Am J Hypertens 1989, 2:875-884.
18. Kline RL, Mercer PF: Effect of captopril and hydralazine on arterial pressure-urinary output relationship in spontaneously hypertensive rats. Hypertension 1987, 10:590-594.
19. Levy BI, Michel JB, Salzmann JL, Azizi M, Poitevin P, Safar ME, et al.: Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. Circ Res 1988, 63:227-239.
20. Michel JB, Dussaule JC, Choudat L, Auzan C, Nochy D, Corvol P, et al.: Effects of antihypertensive treatment in one-clip, two kidney hypertension in rats. Kidney Int 1986, 29:1011-1020.
21. Griffin SA, Brown WC, MacPherson F, McGroer JC, Wilson YG, Karsgaard W, et al.: Angiotensin II cures vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991, 17: 626-635.
22. Wang DH, Prewitt RL: Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension 1990, 15:68-77.
23. Adams MA, Bobik A, Korner PI: Enalapril can prevent vascular amplifier development in spontaneosly hypertensive rats. Hypertension 1990, 16:252-260.
24. Childs TJ, Adams MA, Mak AS: Regression of cardiac hypertrophy in spontaneously hypertensive rats by enalapril and the expression of contractile proteins. Hypertension 1990, 16:662-668.
25. Harrap SB, Van der Merwe WM, Griffin SA, Macpherson F, Lever AF: Brief angiotensin converting enzyme inhibitor in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990, 16:603-614.
26. Morton JJ, Beatie EC, MacPherson F: Angiotensin II receptor anatagonist Losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure. J Vasc Res 1992, 29:264-269.
27. Oddie CJ, Dilley RJ, Kanellakis P, Bobik A: Chronic angiotensin II type 1 receptor antagonism in genetic hypertension: effects on vascular structure and reactivity. J Hypertens 1993, 11:717-724.
28. Unger T, Rettig R: Development of genetic hypertension. Is there a 'critical phase'? Hypertension 1990, 16:615-616.
29. Adams MA, Bobik A, Korner PI: Differential development of vascular and cardiac hypertrophy in genetic hypertension: relation to sympathetic function. Hypertension 1989, 14:191-202.
30. Ferrone RA, Antonaccio MJ: Prevention of the development of spontaneous hypertension in rats by captopril (SQ 14,225). Eur J Pharmacol 1979, 60:131-137.
31. Sen S, Tarazi RC, Bumpus FM: Effect of converting enzyme inhibitor (SQ14,225) on myocardial hypertrophy in spontaneously hypertensive rats. Hypertension 1980, 2:169-176.
32. Richer C, Doussau MP, Guidiceli JF: MK 421 and prevention of genetic hypertension development in young spontaneously hypertensive rats. Eur J Pharmacol 1982, 79:23-29.
33. Harrap SB, Nicolaci JA, Doyle AE: Persistent effects on blood pressure and renal hemodynamics following chronic angiotensin converting enzyme inhibition with perindopril. Clin Exp Pharmacol Physiol 1986, 13:753-765.
34. Black MJ, Adams MA, Bobik A, Campbell JH, Campbell GR: Effect of enalapril on aortic smooth muscle cell polyploidy in the spontaneously hypertensive rat. J Hypertens 1989 7: 997-1003.
35. Christensen HRL, Nielsen H, Christensen KL, Baandrup U, Jespersen LT, Mulvany MJ: Long-term hypotensive effects of an angiotensin converting enzyme inhibitor in spontaneously hypertensive rats: is there a role for vascular structure? J Hypertens 1988, 6 (suppl 3):S27-S31.
36. Christensen KL, Jespersen LT, Mulvany MJ: Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure. J Hypertens 1989, 7:83-90.
37. Fischli W, Hefti F, Clozel JP: Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats. Br J Clin Pharmacol 1989, 27 (suppl 2):151S-158S.
38. Lee RMKW, Berecek KH, Tsoporis J, McKenzie R, Triggle CR: Prevention of hypertension and vascular changes by captopril treatment. Hypertension 1991, 17:141-150.
39. Mulvany MJ, Persson AE, Andresen J: No persistent effect of angiotensin converting enzyme inhibitor treatment in Milan hypertensive rats despite regression of vascular structure. J Hypertens 1991, 9:589-593.
40. Okunishi H, Kawamoto T, Kurobe Y, Oka Y, Ishii K, Tanaka T, et al.: Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 1991, 18:649-659.
41. Hefti F, Fischli W, Gerold M: Cilazapril prevents hypertension in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1986, 8:641-648.
42. Richer C, Mulder P, Fornes P, Richard V, Camilleri JP, Guidicelli JF: Hemodynamic and morphological effects of quinapril during genetic hypertension development. J Cardiovasc Pharmacol 1991, 18:631-642.
43. Oddie CJ, Dilley RJ, Bobik A: Long-term angiotensin II antagonism in spontaneously hypertensive rats: effects on blood pressure and cardiovascular amplifiers. Clin Exp Pharmacol Physiol 1992, 19:392-395.
44. Black MJ, Campbell JH, Campbell GR: Effect of perindopril on cardiovascular hypertrophy of the SHR: respective roles of reduced blood pressure and reduced angiotensin II levels. Am J Cardiol 1993, 71:17E-21E.
45. Gohlke P, Lamberty V, Kuwer I, Bartebach S, Schnell A, Unger T: Vascular remodelling in systemic hypertension. Am J Cardiol 1993, 71:2E-7E.
46. Harrap SB, Mitchell GA, Casley DJ, Mirakian C, Doyle AE: Angiotensin II, sodium and cardiovascular hypertrophy in spontaneously hypertensive rats. Hypertension 1993, 21:50-55.
47. Kost CK Jr, Ping L, Jackson EK: Blood pressure after captopril withdrawal from spontaneously hypertensive rats. Hypertension 1995, 25:82-87.
48. O'Sullivan JB, Harrap SB: Resetting blood pressure in spontaneously hypertensive rats. The role of bradykinin. Hypertension 1995, 25:162-5.
49. Kett MM, Alcorn D, Bertram JF, Anderson WP: Enalapril does not prevent renal arterial hypertrophy in spontaneously hypertensive rats. Hypertension 1995, 25:335-342.
50. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E: Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci USA 1982, 79:3310-3314.
51. Unger T, Moursi M, Ganten D, Hermann K, Lang RE: Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramapril (HOE498). J Cardiovasc Pharmacol 1986, 8:276-285.
52. Clozel JP, Kuhn H, Hefti F: Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 1989, 7:267-275.
53. Frohlich ED, Sasaki O: Dissociation of changes in cardiovascular mass and performance with angiotensin-converting enzyme inhibitors in Wistar-Kyoto and spontaneously hypertensive rats. J Am Coll Cardiol 1990, 16:1492-1499.
54. Frohlich ED, Horinaka S: Cardiac and aortic effects of angiotensin converting enzyme inhibitors. Hypertension 1991, 18 (suppl II):II2-II7.
55. Levy BI, Salzmann JL, Devissaguet M, Safar ME, Michel JB: Angiotensin converting enzyme (ACE) inhibitors in experimental hypertension: influence on heart and arteries. Basic Res Cardiol 1991, 86 (suppl 1):43-53.
56. Gohlke P, Stoll M, Lamberty V, Mattfeld T, Mall G, van Even P, et al.: Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses. J Hypertens 1992, 10 (suppl 6):S141-S144.
57. Ledingham JM, Phelan EL, Millar JA: Effects of cilazapril on the structure of mesenteric resistance arteries of New Zealand genetically hypertensive and normotensive control rats. Clin Exp Pharmacol Physiol 1993, 20:362-364.
58. Levy BI, Michel JB, Salzmann JL, Poitevin P, Devissaguet M, Scalbert E, et al.: Long-term effects of angiotension-converting enzyme inhibition on the arterial wall of adult spontaneously hypertensive rats. Am J Cardiol 1993, 71:8E-16E.
59. Wählander H, Sothell M, Wickman A, Nilsson A, Friberg P: Regression of cardiovascular structural changes with angiotensin converting enzyme inhibitors is dependent on blood pressure reduction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996, 27:327-334.
60. Dunn WR, Gardiner SM: No evidence for vascular remodelling during hypertension induced by chronic inhibition of nitric oxide synthase in Brattleboro rats. J Hypertens 1995, 13:849-858.
61. G-nitro-L-arginine methyl ester-induced hypertension: methodological considerations for studies of small arteries in hypertension. J Hypertens 1995, 13:817-821.
62. G-nitro-L-arginine methyl ester-induced hypertension: methodological considerations for studies of small arteries in hypertension: [reply]. J Hypertens 1995, 13:1217-1220.
63. Schiffrin EL: Author's reply. J Hypertens 1995, 13:1220-1221.
64. Boomsa F, De Bruyn JHB, Derk FHM, Schalekamp MADH: Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response. Clin Sci 1981, 60:491-498
65. Chevillard C, Brown NL, Jouquey S, Mathieu MN, Laliberte F, Hamon G: Cardiovascular actions and tissue-converting enzyme inhibitory effects of chronic enalapril and trandolapril treatment of spontaneously hypertensive rats. J Cardiovasc Pharmacol 1989, 14:297-301.
66. Bianchi G, Barber BR, Ferrari P, Duzzi L: The Milan hypertensive strain of rats and its control normotensive strain. Hypertension 1987, 9 (suppl I):I30-I33.
67. Lever AF: Slow pressor mechanisms in hypertension: a role for hypertrophy of resistance vessels? J Hypertens 1986, 4:515-524.
68. Jennings GL, Esler MD, Korner PI: Effect of prolonged treatment on haemodynamics of essential hypertension before and after autonomic block. Lancet 1980, ii:166-169.
69. Jennings GL, Korner PI, Esler MD, Restall R: Redevelopment of essential hypertension after cessation of longterm therapy: preliminary findings. Clin Exp Hypertens [A] 1984, 6:493-505.
70. Iredale RB, Eccleston-Joyner CA, Roozer RB, Gray SD: Antogenic development of the elastic component of the aortic wall in spontaneously hypertensive rats. Clin Exp Hypertens [A] 1989, 11:173-187.
71. Smeda JS, Lee RM: Effect of hydralazine on the mesenteric vasculature of hypertensive rats. Hypertension 1991, 17: 526-533.
72. Folkow B: Physiological aspects of primary hypertension. Physiol Rev 1982, 62:347-504.
73. Folkow B: The 'structural factor' in hypertension: with special emphasis on the hypertrophic adaptation of the systemic resistance vessels. In Hypertension. Pathophysiology, Diagnosis and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press Ltd; 1990:565-581.
74. Folkow B: Physiological aspects of primary hypertension. Physiol Res 1982, 62:347-504.
75. Hallback M, Gothberg G, Lundin S, Riorsten SE, Folkow B: Hemodynamic consequences of resistance vessel rarefaction and of drugs in smooth muscle sensitivity. Acta Physiol Scand 1976, 97:233-240.
76. Guyton AC: Arterial Pressure and Hypertension. Philadelphia: W.B. Saunders; 1986.
77. Guyton AC: Renal function curve - a key to understanding the pathogenesis of hypertension. Hypertension 1987, 10:1-6.
78. Guyton AC, Coleman TG, Cowley AW, Scheel KW, Manning RD, Norman RA: Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972, 52:584-594.
79. Guyton AC, Hall JE, Coleman TG, Manning RD Jr: The dominant role of the kidneys in the long-term regulation of arterial pressure in normotensive and hypertensive states. In Hypertension. Pathophysiology, Diagnosis and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1990:1029-1052.
80. Guyton AC, Manning RD, Hall JE, Norman R, Young DB, Pan YJ: The pathogenic role of the kidney. J Cardiovasc Pharmacol 1984, 6 (suppl 1):S151-S161.
81. Borst JGG, Borst-deGues A: Hypertension explained by Starling's theory of circulatory homeostasis. Lancet 1963, 677-682.
82. Starling EH: On the absorption of fluids from the connective tissue spaces. J Physiol 1895-1896, 19:312-326
83. Cowley AW Jr: Long-term control of arterial blood pressure. Physiol Rev 1992, 72:231-300.
84. Luke RG: Essential hypertension: a renal disease? A review and update of the evidence. Hypertension 1993, 21:380-390.
85. Gothberg G, Folkow B: 'Structural autoregulation' of the preglomerular/postglomerular resistance ratio and hence of glomerular filtration rate in the clipped (low pressure) kidney in two-kidney, one-clip renal hypertension. Clin Sci 1982, 63 (suppl 8): 359s-362s.
86. Gothberg G, Folkow B: Age-dependent alterations in the structurally determined vascular resistance, pre- to postglomerular resistance ratio and glomerular filtration capacity in kidneys, as studied in aging normotensive and spontaneously hypertensive rats. Acta Physiol Scand 1983, 117:547-555.
87. Gothberg G, Hallback M, Lundin S, Ricksten SE, Folkow B: A comparison of renal flow resistance in normotensive control rats and spontaneously hypertensive rats (SHR). Clin Exp Pharmacol Physiol 1976, 3 (suppl 3):79-82.
88. Gothberg G, Hallback-Norlander M, Karlstrom G, Ricksten S-E, Folkow B: Structurally based changes of renal vascular reactivity in spontaneously hypertensive and two-kidney, one-clip renal hypertensive rats, as compared with kidneys from uninephrectomized and intact normotensive rats. Acta Physiol Scand 1983, 118: 61-67.
89. Gothberg G, Lundin S, Ricksten S-E, Folkow B: Apparent and true resistances to flow in SHR and NCR kidneys as related to the pre/postglomerular resistance ratio. Acta Physiol Scand 1979, 105:282-294.
90. Goldblatt H: The renal origin of hypertension. Physiol Rev 1947, 27:120-165.
91. Goldblatt H, Lynch J, Hanzal RF, Summerville WW: Studies on experimental hypertension. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934, 59:347-379.
92. Goldblatt PJ: The Goldblatt Experiment. A conceptual paradigm. In Hypertension. Pathophysiology, Diagnosis and Management. Edited by Laragh JH, Brenner BM, New York: Raven Press; 1990:21-32.
93. Bianchi G, Fox U, Di Francesco GF, Giovannetti AM, Pagetti D: Blood pressure changes produced by kidney cross-transplantation between spontaneously hypertensive rats (SHR) and normotensive rats (NR). Clin Sci Mol Med 1974, 47:435-448.
94. Curtis JJ, Luke RG, Dustan HP, Kashgarian M, Whelchel JD, Jones P, et al.: Remission of essential hypertension after renal transplantation. N Engl J Med 1983, 309:1009-1015.
95. Dahl LK, Heine M: Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res 1975, 36:692-696.
96. Dahl LK, Heine M, Thompson K: Genetic effect of renal homografts on the blood pressure of rats from different strains. Proc Soc Exp Biol Med 1972, 140:852-856,
97. Dahl LK, Heine M, Thompson K: Genetic influence of the kidneys on blood pressure. Circ Res 1974, 34:94-101.
98. Dal Palu C, Pessina AC, Pagnan A, Pauletto P, Lusiani L, Ronsisvalle G, et al.: Effect of captopril on left ventricular mass and function in hypertensive patients and in the rat. Postgrad Med J 1986, 62 (suppl 11):85-89.
99. Morgan DA, DiBona GF, Mark AL: Effects of interstrain renal transplantation on NaCl-induced hypertension in Dahl rats. Hypertension 1990, 15:436-442.
100. Rettig R, Stauss H, Folberth C, Ganten D, Waldherr R, Unger T: Hypertension transmitted by kidneys from stroke-prone spontaneously hypertensive rats. Am J Physiol 1989, 257:F197-F203.
101. Rettig R, Schmitt B, Pelzl B, Speck T: The kidney and primary hypertension: contributions from renal transplantation studies in animals and humans. J Hypertens 1993, 11:883-891.
102. Rettig R, Unger T: The role of the kidney in the aetiology of hypertension: renal transplantation studies in rats. Trends Pharmacol Sci 1991, 12:243-245.
103. Strandgaard S, Hansen U: Hypertension in renal allograft recipients may be conveyed by cadaveric kidneys from donors with subarachnoid haemorrage. BMJ 1986, 292:1042-1044.
104. Friberg P, Sundelin B, Boman S-O, Bobik A, Nilsson H, Wickman A, et al.: RAS in neonatal rats: induction of a renal abnormality in response to ACE inhibition or angiotensin II antagonism. Kidney Int 1994, 45:485-492.